[HTML][HTML] Visceral leishmaniasis: experimental models for drug discovery
S Gupta - Indian Journal of Medical Research, 2011 - journals.lww.com
Visceral leishmaniasis (VL) or kala-azar is a chronic protozoan infection in humans
associated with significant global morbidity and mortality. The causative agent is a …
associated with significant global morbidity and mortality. The causative agent is a …
Visceral leishmaniasis: Experimental models for drug discovery.
S Gupta - Indian Journal of Medical Research, 2011 - search.ebscohost.com
Visceral leishmaniasis (VL) or kala-azar is a chronic protozoan infection in humans
associated with significant global morbidity and mortality. The causative agent is a …
associated with significant global morbidity and mortality. The causative agent is a …
Visceral leishmaniasis: experimental models for drug discovery.
SG Suman Gupta, N Nishi - 2011 - cabidigitallibrary.org
Visceral leishmaniasis (VL) or kala-azar is a chronic protozoan infection in humans
associated with significant global morbidity and mortality. The causative agent is a …
associated with significant global morbidity and mortality. The causative agent is a …
Visceral leishmaniasis: Experimental models for drug discovery.
S Gupta - 2011 - pesquisa.bvsalud.org
Visceral leishmaniasis (VL) or kala-azar is a chronic protozoan infection in humans
associated with significant global morbidity and mortality. The causative agent is a …
associated with significant global morbidity and mortality. The causative agent is a …
Visceral leishmaniasis: experimental models for drug discovery
S Gupta, N Gupta - Indian Journal of Medical Research, 2011 - go.gale.com
Visceral leishmaniasis (VL) or kala-azar is a chronic protozoan infection in humans
associated with significant global morbidity and mortality. The causative agent is a …
associated with significant global morbidity and mortality. The causative agent is a …
[HTML][HTML] Visceral leishmaniasis: Experimental models for drug discovery
S Gupta - The Indian Journal of Medical Research, 2011 - ncbi.nlm.nih.gov
Visceral leishmaniasis (VL) or kala-azar is a chronic protozoan infection in humans
associated with significant global morbidity and mortality. The causative agent is a …
associated with significant global morbidity and mortality. The causative agent is a …
Visceral leishmaniasis: experimental models for drug discovery.
S Gupta - The Indian Journal of Medical Research, 2011 - europepmc.org
Visceral leishmaniasis (VL) or kala-azar is a chronic protozoan infection in humans
associated with significant global morbidity and mortality. The causative agent is a …
associated with significant global morbidity and mortality. The causative agent is a …
Visceral leishmaniasis: Experimental models for drug discovery
S Gupta - The Indian Journal of Medical Research, 2011 - search.proquest.com
Visceral leishmaniasis (VL) or kala-azar is a chronic protozoan infection in humans
associated with significant global morbidity and mortality. The causative agent is a …
associated with significant global morbidity and mortality. The causative agent is a …
Visceral leishmaniasis: experimental models for drug discovery
S Gupta - The Indian journal of medical research, 2011 - pubmed.ncbi.nlm.nih.gov
Visceral leishmaniasis (VL) or kala-azar is a chronic protozoan infection in humans
associated with significant global morbidity and mortality. The causative agent is a …
associated with significant global morbidity and mortality. The causative agent is a …
Visceral leishmaniasis: Experimental models for drug discovery.
S Gupta - Indian Journal of Medical Research, 2011 - search.ebscohost.com
Visceral leishmaniasis (VL) or kala-azar is a chronic protozoan infection in humans
associated with significant global morbidity and mortality. The causative agent is a …
associated with significant global morbidity and mortality. The causative agent is a …